• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

地奥司明——分离技术、植物材料和药物制剂中的测定方法以及临床应用。

Diosmin--isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use.

作者信息

Bogucka-Kocka Anna, Woźniak Michał, Feldo Marcin, Kockic Janusz, Szewczyk Katarzyna

机构信息

Chair and Department of Pharmaceutical Botany, Medical University, Lublin, 20-093 Chodźki 1, Poland.

出版信息

Nat Prod Commun. 2013 Apr;8(4):545-50.

PMID:23738475
Abstract

Diosmin is a naturally occurring flavone glycoside used in the treatment of venous diseases. In this review, we present the clinical aspects of the use of diosmin preparations in venous stasis, hemorrheologic disorders and vein wall remodeling. Because of its multiple applications in biology and its many therapeutic activities, research on isolation and identification of diosmin is of high relevance. The aim of this review is to present an overview of techniques of isolation and separation of diosmin in plant material, pharmaceutical formulations such as Daflon, Diosed and Dioven tablets, and biological fluids.

摘要

地奥司明是一种天然存在的黄酮糖苷,用于治疗静脉疾病。在本综述中,我们介绍了地奥司明制剂在静脉淤滞、血液流变学紊乱和静脉壁重塑方面的临床应用情况。由于其在生物学中的多种应用及其众多治疗活性,地奥司明的分离与鉴定研究具有高度相关性。本综述的目的是概述从植物材料、诸如达弗隆、迪奥斯德和迪奥文片等药物制剂以及生物流体中分离和提纯地奥司明的技术。

相似文献

1
Diosmin--isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use.地奥司明——分离技术、植物材料和药物制剂中的测定方法以及临床应用。
Nat Prod Commun. 2013 Apr;8(4):545-50.
2
Improved LC methods for the determination of diosmin and/or hesperidin in plant extracts and pharmaceutical formulations.用于测定植物提取物和药物制剂中地奥司明和/或橙皮苷的改进液相色谱法。
J Pharm Biomed Anal. 2001 Nov;26(4):539-45. doi: 10.1016/s0731-7085(01)00476-9.
3
Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.与非微粉化地奥司明相比,微粉化类黄酮组分(爱脉朗500毫克)的优势。
Angiology. 1994 Jun;45(6 Pt 2):531-6.
4
Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting.通过加速器质谱法和液体闪烁计数法对健康志愿者口服微粉化(达弗隆500毫克)和非微粉化14C - 地奥司明片后的吸收情况进行比较。
J Pharm Sci. 2002 Jan;91(1):32-40. doi: 10.1002/jps.1168.
5
Controlled studies of Daflon 500 mg in chronic venous insufficiency.对500毫克达芙通治疗慢性静脉功能不全的对照研究。
Angiology. 1994 Jun;45(6 Pt 2):549-53.
6
Selection of hybrids and edible citrus species with a high content in the diosmin functional compound. Modulating effect of plant growth regulators on contents.筛选含有高含量地奥司明功能化合物的杂交柑橘品种和可食用柑橘品种。植物生长调节剂对其含量的调节作用。
J Agric Food Chem. 2001 Jul;49(7):3356-62. doi: 10.1021/jf010052n.
7
Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.5682 SE治疗静脉功能不全的药效学和临床活性双盲研究。新型微粉化形式的优势。
Int Angiol. 1989 Oct-Dec;8(4 Suppl):61-5.
8
Hemorheological improvement after Daflon 500 mg treatment in diabetes.糖尿病患者服用500毫克达弗隆后的血液流变学改善情况。
Int Angiol. 1988 Apr-Jun;7(2 Suppl):21-4.
9
Pharmacology of Diosmin, a Citrus Flavone Glycoside: An Updated Review.地奥司明的药理学:一个柑橘黄酮糖苷:更新综述。
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):1-18. doi: 10.1007/s13318-021-00731-y. Epub 2021 Oct 23.
10
Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency.500毫克达弗隆治疗6个月对伴有慢性静脉功能不全的下肢静脉溃疡患者的疗效
Int Angiol. 2003 Mar;22(1):24-31.

引用本文的文献

1
Diosmin Administration Slightly Counteracted the Changes in Bone Mechanical Properties Induced by Experimental Type 1 Diabetes in Rats.地奥司明给药略微抵消了实验性1型糖尿病诱导的大鼠骨力学性能变化。
Pharmaceuticals (Basel). 2025 May 13;18(5):715. doi: 10.3390/ph18050715.
2
Diosmin Potentiates the Antidiabetic Effects of Linagliptin in Nicotinamide/Streptozotocin-Induced Diabetic Wistar Rats.地奥司明增强利格列汀对烟酰胺/链脲佐菌素诱导的糖尿病Wistar大鼠的抗糖尿病作用。
Pharmaceuticals (Basel). 2025 Apr 29;18(5):656. doi: 10.3390/ph18050656.
3
A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.
系统评价:槲皮素,黄酮醇类的次生代谢产物,具有多种健康益处和低生物利用度。
Int J Mol Sci. 2024 Nov 11;25(22):12091. doi: 10.3390/ijms252212091.
4
Diosmin: A promising phytochemical for functional foods, nutraceuticals and cancer therapy.地奥司明:一种用于功能性食品、营养保健品及癌症治疗的颇具潜力的植物化学物质。
Food Sci Nutr. 2024 Jun 18;12(9):6070-6092. doi: 10.1002/fsn3.4271. eCollection 2024 Sep.
5
Hepatoprotective effects of diosmin: a narrative review.地奥司明的肝脏保护作用:一篇叙述性综述
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):279-295. doi: 10.1007/s00210-024-03297-z. Epub 2024 Aug 21.
6
New Insights for Polyphenolic Compounds as Naturally Inspired Proteasome Inhibitors.多酚类化合物作为天然来源蛋白酶体抑制剂的新见解
Pharmaceuticals (Basel). 2023 Dec 11;16(12):1712. doi: 10.3390/ph16121712.
7
Aspiration with Diosmin Intake in Endometrial Cavity Fluid Accumulation in ART Cycles: A Randomized Controlled Trial.地奥司明吸入治疗辅助生殖技术周期中子宫内膜腔积液的随机对照试验
J Obstet Gynaecol India. 2023 Aug;73(4):336-342. doi: 10.1007/s13224-023-01791-7. Epub 2023 Aug 31.
8
Design of an Herbal Preparation Composed by a Combination of L. and L. Extracts, Magnolol and Diosmetin to Address Chronic Venous Diseases through an Anti-Inflammatory Effect and AP-1 Modulation.一种由罗勒提取物和光果甘草提取物、厚朴酚与香叶木素组合而成的草药制剂的设计,旨在通过抗炎作用和AP-1调节来治疗慢性静脉疾病。
Plants (Basel). 2023 Feb 26;12(5):1051. doi: 10.3390/plants12051051.
9
Diosmin-Loaded Nanoemulsion-Based Gel Formulation: Development, Optimization, Wound Healing and Anti-Inflammatory Studies.基于纳米乳剂的地奥司明凝胶制剂:研发、优化、伤口愈合及抗炎研究
Gels. 2023 Jan 22;9(2):95. doi: 10.3390/gels9020095.
10
Plant metabolite diosmin as the therapeutic agent in human diseases.植物代谢产物地奥司明作为人类疾病的治疗剂。
Curr Res Pharmacol Drug Discov. 2022 Aug 13;3:100122. doi: 10.1016/j.crphar.2022.100122. eCollection 2022.